← Eichor
Study identifier: NCT06774326 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Role of Spectral CT in the Evaluation of Cardiotoxicity in Patients With Hodgkin's Lymphoma and Diffuse Large B-cell Lymphoma Treated With Anthracyclines

Condition: Cardiac Imaging · Cardiac Imaging Techniques · Lymphoma  ·  Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna

PhaseN/A
Planned participants160
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

To evaluate the diagnostic capability of Spectral CT (performed with contrast agent as part of routine oncological follow-up) in detecting signs of acute and chronic early-onset cardiac toxicity from anthracyclines in patients with Hodgkin's lymphoma and diffuse large B-cell lymphoma undergoing treatment regimens that include a drug from this family.

This description comes directly from the study's public registry record.

Talk to the study team

Vincenzo Russo, MD  ·  +390512144747  ·  vincenzo.russo@aosp.bo.it

Always discuss trial participation with your own doctor first.

Locations (1)

IRCCS Azienda Ospedaliero-Universitaria di BolognaBologna, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06774326